BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update

February 18, 2016 4:05 PM EST

Key advancements within three blockbuster opportunities: IBS-C/CIC, vascular/fibrotic diseases and refractory GERD

LINZESS® (linaclotide) U.S. net sales increased ~53% to $455 million in 2015; on track to exceed $1 billion in net sales by 2020

Ironwood revenue increased >95% to $150 million in 2015, primarily driven by continued growth in LINZESS net sales and expansion in commercial margin to ~46%

Delivered on 2015 financial guidance with strong business execution

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More